

— OFFICIALLY LICENSED —

BEST OF ASCO®

2015 ANNUAL MEETING

www.asco.org



SLS
SLOVENSKÁ LEKÁRSKA SPOLOČNOSŤ

SOLEN
MEDICAL EDUCATION

Program

„Best of ASCO® Slovakia 2015“

Best of ASCO® event in Slovakia 2015

A program license by the American Society of Clinical Oncology

7. ročník / 7th Annual

10th October 2015 | Holiday Inn, Bratislava, Slovakia

Place: Holiday Inn, Bratislava

Date: 10th, October 2015

Official language: Slovak

8.00 – 8.30 **Registration**

8.30 – 8.35 **Welcome**
President of Slovak Oncology Society, Tomáš Šálek

I. Breast Cancer Session

Chairmen: *Mária Wagnerová, Stanislav Špánik*

(8.35 – 9.35)

8.35 – 8.55

1. Breast Cancer – HER2/ER+ (Eva Oravcová, NOÚ Bratislava)

1. Abstract # LBA500 (146144) **Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.** (Richard G. Margoless)
2. Abstract # 508 (149972) **Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).** (Arlene Chan)
3. Abstract # 504 (145508) **Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial.** (Michael Gnat)
4. Abstract # LBA502 (154447) **PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.** (Nicholas C. Turner)
5. Abstract # 507 (147990) **Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.** (Paul Anthony Ellis)
6. Abstract # 1001 (1147950) **Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician's Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.** (Edith A. Perez)

8.55 – 9.15

2. Breast Cancer – Triple-Negative/Local Therapy

(Bibiana Vertáková-Krakovská, OÚSA Bratislava)

1. Abstract # 1002 (147276) **Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC).** (Marco Colleoni)
2. Abstract # 1003 (150040) **Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).** (Tiffany A. Traina)

3. Abstract # 1008 (146776) **Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.** (David Krug)

4. Abstract # 1006 (142462) **The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.** (Yasuaki Sagara)

9.15 – 9.35

Discussion

II. Genitourinary Cancer / Gynecologic Cancer Session

Chairmen: Vladimír Malec, Jozef Mardiak

(9.35 – 10.45)

9.35 – 9.55

3. Genitourinary Cancer (Michal Mego, NOÚ, Bratislava)

1. Abstract # 5001 (147721) **Docetaxel and/or zoledronic acid for hormone-naive prostate cancer: First overall survival results from STAMPEDE (NCT00268476).** (Nicholas David James)

2. Abstract # LBA5002 (144388) **A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521).** (Howard M. Sadler)

3. Abstract # 5006 (147682) **Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial—NCT00423475.** (Christian Carrie)

4. Abstract # 5007 (150983) **TROG 03.06 and VCOG PR 01-03: The “timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)” collaborative randomised phase III trial.** (Gillian M. Duchesne)

5. Abstract # 5004 (145799) **Defining a molecular subclass of treatment resistant prostate cancer.** (Himisha Beltran)

6. Abstract # 4503 (152881) **First-line randomized phase II study of gemcitabine/cisplatin plus apatersen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial.** (Joaquim Bellmunt)

7. Abstract # 4505 (148692) **A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients.** (Thomas Powles)

8. Abstract # 4506 (144564) **Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mRCC).** (Robert Motzer)

9. Abstract # 4507 (147311) **Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN).** (Andrew J. Armstrong)

9.55 – 10.15

4. Gynecologic Cancer (Jozef Šufliarsky, NOÚ Bratislava)

1. Abstract #5500 (144077) **A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.** (Carol Aghajanian)
2. Abstract #5508 (150121) **Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.** (Iain A. McNeish)
3. Abstract #5509 (147268) **Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, open-label expansion trial.** (Mary L. Disis)
4. Abstract #5522 (143154) **CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study.** (Ting-Yim Lee)

10.15 – 10.45 Discussion

10.45 – 11.00 Coffee-Break

III. Head&Neck Cancer / Melanoma&Skin Cancers Session

Chairmen: Juraj Beniak, Dagmar Sorkovská

(11.00 – 12.00)

11.00 – 11.20

5. Head&Neck Cancer (Marek Marinčák, VOÚ Košice)

1. Abstract # LBA3 (151578) **Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT).** (Anil D'Cruz)
2. Abstract # 6000 (149178) **Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial.** (Lillian L. Siu)
3. Abstract # LBA6008 (149051) **Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort.** (Tanguy Y. Seiwert)
4. Abstract # 6005 (146171) **Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma.** (Eleni Marie Rettig)
5. Abstract # 6009 (149962) **PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT).** (Hisham Mohamed Mehanna)

11.20 – 11.40

6. Melanoma&Skin Cancers (Zuzana Pribulová, VOÚ Košice)

1. Abstract # LBA1 (144621) **Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients (pts) with advanced melanoma (MEL) (CheckMate 067).** (Jedd D. Wolchok)
2. Abstract # 102 (149861) **Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.** (Georgina V. Long)
3. Abstract # 9001 (143627) **Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma.** (Andrew J Hayes)
4. Abstract # LBA9002 (146329) **Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial.** (Ulrike Leiter)
5. Abstract # 9000 (149209) **Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.** (Andrew James Martin)

11.40 – 12.00

Discussion

12.00 – 13.30

Lunch

IV. Lung Cancer&Mesothelioma / Patient and Survivor Care Session

Chairmen: Peter Beržinec, Jozef Chovanec

(13.30 – 14.40)

13.30 – 13.50

7. Patient and Survivor Care (Olga Szegheöová, FN Nové Zámky)

1. Abstract # LBA2 (148284) **Reduction in late mortality among 5-year survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).** (Gregory T. Armstrong)
2. Abstract # 9500 (149475) **Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2).** (Jennifer S. Temel)
3. Abstract # 9501 (147845) **CALGB 70604 (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer.** (Andrew Louis Himmelstein)
4. Abstract # 9503 (152832) **Chemotherapy-related cognitive impairment (CRCI), and neurotransmitter signaling, longevity, and inflammation pathways in 366 breast cancer (BC) patients and 366 age-matched cancer-free controls: A prospective, nationwide, longitudinal URCC NCORP study.** (Michelle Christine Janelsins)
5. Abstract # 9521 (145384) **Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer.** (Kutluk Oktay)

13.50 – 14.20

8. Lung Cancer&Mesothelioma (Gabriela Chowanecová, ŠN sv. Svorada, Nitra)

1. Abstract # LBA4 (146056) **NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases.** (Paul D. Brown)
2. Abstract # 8005 (149588) **Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).** (Paula Mary Mulvenna)
3. Abstract # LBA109 (154634) **Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).** (Luis Paz-Ares)
4. Abstract # 8001 (152181) **Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive non-small cell lung cancer (NSCLC) patients (pts).** (Lecia V. Sequist)
5. Abstract # 8006 (147124) **Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC).** (David Planchard)
6. Abstract # LBA8010 (150315) **Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR).** (Alexander I. Spira)
7. Abstract # 7502 (148558) **Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028.** (Patrick Alexander Ott)
8. Abstract # 7503 (146138) **Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032.** (Scott Joseph Antonia)
9. Abstract # 7506 (144034) **Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC).** (Suresh Senan)
10. Abstract # 7507 (150635) **Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected non-small cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract:2007-000067-15; NCTgov: 00478699).** (Bartomeu Massuti)
11. Abstract # 7500 (150191) **Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS randomized phase 3 trial.** (Gerard Zalcman)

14.20 – 14.40

Discussion

14.40 – 14.55

Coffee-Break

V. Gastrointestinal Cancer Session

Chairmen: Tomáš Šálek, Igor Andrašina

(14.55 – 15.55)

14.55 – 15.15

9. Gastrointestinal cancer (Colorectal) (Marián Kakalejčík, POKO Poprad)

1. Abstract # 3500 (147521) **A multi-center randomized controlled trial of mFOLFOX6 with or without radiation in neoadjuvant treatment of local advanced rectal cancer (FOWARC study): Preliminary results.** (Yanhong Deng)
2. Abstract # 3501 (151361) **Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC).** (Theo Ruers)
3. Abstract # 3502 (145884) **SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).** (Peter Gibbs)
4. Abstract # 3503 (149805) **Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 80405 (Alliance).** (Kimmie Ng)
5. Abstract # 3504 (146901) **Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.** (Simer Bains)

15.15 – 15.35

10. Gastrointestinal (Non-Colorectal) Cancer (Branislav Bystrický, FNŠP Trenčín)

1. Abstract # 4000 (147255) **Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study.** (David Cunningham)
2. Abstract # 4001 (150958) **Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012.** (Yung-Jue Bang)
3. Abstract # 4005 (150169) **Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pNET), CALGB 80701 (Alliance).** (Matthew H. Kulke)

15.35 – 15.55

Discussion

15.55 – 16.00

Closing remarks

President of Slovak Oncology Society, Tomáš Šálek

FAREWELL

PRÍZVSKO, MENO, TITUL (čitateľne):
SURNAME, NAME, TITLE (LEGIBLY): _____

ADRESA PRÁCOVISA:
WORK ADDRESS: _____

TEL., FAX: _____ **E-MAIL:** _____

REG. Č. SLOVENSKEJ LEKÁRSKEJ KOMORY:
REG. NUMBER OF THE SLOVAK MEDICAL CHAMBER: _____

REGISTRAČNÝ POPLATOK 3 € (PLATBA NA MIESTE MOŽNÁ LEN V HOTOVOSTI)
REGISTRATION FEE 3 € (PAYMENT ON THE SPOT IS POSSIBLE ONLY IN CASH)

ZÁVÄZNÁ OBJEDNÁVKA UBYTOVANIA V HOTELI HOLIDAY INN (DO 9. 9. 2015)
/ OBLIGATORY ORDER OF THE ACCOMMODATION IN THE HOLIDAY INN (T.O 9. 9. 2015)

(Na základe vyplnenej príhlášky Vám bude obratom zaslaná zálohová faktúra na ubytovanie.)
 dvojložková izba – **99 €** (cena je uvedená s DPH, zahŕňa ubytovanie na 1 noc, raňajky, miestny poplatok)

Mám záujem o ubytovanie z 9. na 10. 10. 2015
I would like to book a room from 9th till 10th of October 2015

áno/Yes nie/No

CHCEM BYŤ UBYTOVANÝ(A) S:
I WOULD LIKE TO SHARE A ROOM WITH: _____

Príhlášky zasielajte najneskôr do **9. 9. 2015** (ubytovanie) alebo do **2. 10. 2015** (účast').
The deadline for application is 19th of September 2015 (accommodation) or 2nd October 2015 (attendance).

Týmto dávam súhlas spoločnosti SOLENN s.r.o. na spracovanie mojich osobných údajov, uvedených v tomto dokumente na účel spracovania príhlášok a rozšielanie informácií, e-mailov v zmysle zák. č. 122/2013 Z.z. o ochrane osobných údajov. Tento súhlas je možný kedykoľvek odvolať písomnou formou.

I hereby give permission to the SOLENN Company for the usage of my personal data that is presented in this document for the purpose of the processing of the application forms and for the distribution of information emails according to the act No. 122/2013. The act No. 482/2002 deals with security of personal data. This permission may be cancelled anytime in writing.

Rezervácia ubytovania je záväzná, zmena je možná bez účtovania storno poplatku do 9. 9. 2015. Po tomto dátume bude nautčovaný 100 % storno poplatok.
Reservation of the accommodation is obligatory and the changes of the reservations can be done without any fees until 9th of September 2015. After 9th of September 2015, there will be charged a 100% cancellation fee.

Vyplnenú príhlášku prosíme zaslať na adresu organizátora pošťou, mailom, faxom (02/5465 1384).
Organizátor: SOLENN s. r.o., Ambrova 5, 831 01 Bratislava, e-mail: kongres@solenn.sk
Please, send completed Application Form to the address of the organizer by mail, email or fax (+421 2 54651 384).
Organizer: SOLENN s. r.o., Ambrova 5, 831 01 Bratislava, e-mail: kongres@solenn.sk

Akceptujeme aj príhlášku cez web stránku spoločnosti SOLENN, s. r. o. na adrese: www.solenn.sk v sekcii Kongresy a semináre. Telefónické prihlásenie na podujatie nie je možné.
We accept the registration through the web page of organizer SOLENN s.r.o.: www.solenn.sk in the section "Kongresy a semináre".
There is no possibility of the registration by phone.